Zentalis Pharmaceuticals (ZNTL) Preferred Stock Liabilities (2019 - 2020)

Zentalis Pharmaceuticals' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $155.9 million for Q1 2020.

• In Q1 2020, Preferred Stock Liabilities changed N/A year-over-year to $155.9 million; the TTM figure through Mar 2020 stood at $155.9 million (changed N/A YoY), while the FY2019 annual figure was $141.7 million, changed N/A from the prior year.
• Preferred Stock Liabilities for Q1 2020 stood at $155.9 million, up from $141.7 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $155.9 million in Q1 2020, with the low at $141.7 million in Q4 2019.